Obama reignites 7-year biosimilar exclusion and inflames "innovators"
This article was originally published in Scrip
Executive Summary
With the Republicans baying for greater austerity cuts, President Barack Obama has thrown them a drug-related scrap. However, parts of the industry may find that scrap somewhat indigestible. In his $3.73 trillion fiscal year 2012 budget announced 14 February is a proposal that seeks to reduce from 12 to seven the years of data exclusivity protection for "innovator" biologics against follow-on biologics.